Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study

Pediatric Blood and Cancer

Volumn 62, Issue 1, 2015, Pages 40-44

  van Maldegem, Annemiek M ^a   Benson, Charlotte ^b   Rutkowski, Piotr ^c   Blay, Jean Yves ^d   van den Berg, Henk ^e   Placzke, Joanna ^c   Rasper, Meybrit ^f   Judson, Ian ^b   Juergens, Heribert ^f   Dirksen, Uta ^f   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d CENTRE LÉON BÉRARD   (France)

^e EMMA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Etoposide; Ewing sarcoma; Outcome; Platinum; Prognostic factor; Retrospective

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EUROPE; EWING SARCOMA; FEMALE; HEARING IMPAIRMENT; HUMAN; KIDNEY FAILURE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS RESECTION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; BONE NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SALVAGE THERAPY; SARCOMA, EWING; SECONDARY; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SARCOMA, EWING; SURVIVAL RATE; YOUNG ADULT;

EID: 84922824223     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25230     Document Type: Article

References (27)

1. Cotterill SJ, Parker L, Malcolm AJ, et al. Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: A report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer 2000; 83:397-403.
2. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108-3114.
3. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 2008; 3:e1965.
4. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61:23-32.
5. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study. J Clin Oncol 2009; 27:2536-2541.
6. Thacker MM, Temple HT, Scully SP. Current treatment for Ewing's sarcoma. Expert Rev Anticancer Ther 2005; 5:319-331.
7. Rodriguez-Galindo C, Navid F, Liu T, et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol 2008; 19:814-820.
8. Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549-553.
9. Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34:1514-1521.
10. Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 2012; 17:321.
11. Mora J, Cruz CO, Parareda A, de TC. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009; 31:723-729.
12. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113:419-425.
13. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 2012; 59:854-858.
14. Van WP, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005; 44:338-347.
15. Fu S, Hou MM, Wheler J, et al. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs 2013.
16. Takayama K, Inoue K, Tokunaga S, et al. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK040. Cancer Chemother Pharmacol 2013; 72:1353-1359.
17. Twelves C, Chmielowska E, Havel L, et al. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol 2014; 25:132-138.
18. Wang L, Wu S, Ou G, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012; 77:89-96.
19. Yilmaz U, Polat G, Anar C, Halilcolar H. Carboplatin plus etoposide for extensive stage small-cell lung cancer: An experience with AUC 6 doses of carboplatin. Indian J Cancer 2011; 48:454-459.
20. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26:649-655.
21. El WA, Memon M, Raja M, et al. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. Am J Clin Oncol 2004; 27:529-534.
22. Whelan JS, McTiernan A, Kakouri E, Kilby A. Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 2004; 43:237-242.
23. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47:795-800.
24. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48:132-139.
25. Ferrari S, del Prever AB, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009; 52:581-584.
26. Kebudi R, Cakir FB, Gorgun O, et al. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors. Pediatr Hematol Oncol 2013; 30:170-177.
27. Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer 2013; 60:1621-1625.